Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

[Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].

Christensen M, Vilsbøll T, Knop FK.

Ugeskr Laeger. 2012 Aug 20;174(34):1935; discussion 1935. Danish. No abstract available.

PMID:
23077741
2.

Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.

Edwards CM.

Br J Hosp Med (Lond). 2013 Apr;74(4):198-201. Review. No abstract available.

PMID:
23571389
3.

Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.

Moses A.

BMJ. 2013 Jul 10;347:f4386. doi: 10.1136/bmj.f4386. No abstract available.

PMID:
23842435
4.

Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?

Olansky L.

Cleve Clin J Med. 2010 Aug;77(8):503-5. doi: 10.3949/ccjm.77a.09167. No abstract available.

PMID:
20682512
5.

The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies.

Zinman B.

Diabetes Obes Metab. 2009 Dec;11 Suppl 3:1-3. doi: 10.1111/j.1463-1326.2009.01071.x. No abstract available.

PMID:
19878255
6.

[DPP-IV inhibitors and GLP-1 analogues].

Zettl H, Steinhilber D.

Pharm Unserer Zeit. 2010 Mar;39(2):108-13. doi: 10.1002/pauz.201000357. Review. German. No abstract available. Erratum in: Pharm Unserer Zeit. 2010 May;39(3):168.

PMID:
20196037
7.

Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.

Yoshida M, Asai M, Miyata M, Ogawa K, Maeda H, Oiso Y.

Diabetes Res Clin Pract. 2012 Jun;96(3):e55-6. doi: 10.1016/j.diabres.2011.12.024. Epub 2012 Jan 16. No abstract available.

PMID:
22257418
8.

Insulin treatment for type 2 diabetes: when to start, which to use.

Hamaty M.

Cleve Clin J Med. 2011 May;78(5):332-42. doi: 10.3949/ccjm.78a.10051. Review.

PMID:
21536829
9.

[Liraglutide in the treatment of diabetes type 2].

Novak B, Metelko Z.

Lijec Vjesn. 2011 Jul-Aug;133(7-8):269-76. Review. Croatian.

PMID:
22165195
10.

[Glucagon-like peptide 1 analogues in the treatment of type 2 diabetes mellitus].

Beck-Nielsen H.

Ugeskr Laeger. 2012 Jun 4;174(23):1606-8. Danish.

PMID:
22673382
11.

Current challenges in type 2 diabetes.

Garber AJ.

Diabetes Obes Metab. 2012 Apr;14 Suppl 2:1-3. doi: 10.1111/j.1463-1326.2012.01572.x. No abstract available.

PMID:
22405263
12.

Glucagon-like peptide-1 and diabetes 2012.

Monami M, Di Pasquale G, Rowzee A, Rotella CM, Mannucci E.

Exp Diabetes Res. 2012;2012:768760. doi: 10.1155/2012/768760. Epub 2012 Dec 31. No abstract available.

13.

[Antidiabetics and the incretin system].

Høibraaten E, Folkersen J.

Tidsskr Nor Laegeforen. 2008 Sep 11;128(17):1985. Norwegian. No abstract available.

14.

What's new in diabetes: incretins and C-peptide.

Marks V.

Med Princ Pract. 2011;20(2):101-2. doi: 10.1159/000321278. Epub 2010 Sep 16. Review. No abstract available.

15.

The safety of incretin based drugs.

Montori VM.

BMJ. 2014 Apr 24;348:g2779. doi: 10.1136/bmj.g2779. No abstract available.

PMID:
24764568
16.

[Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].

Fabreegas B.

Soins. 2008 Jun;(726):34-7. French. No abstract available.

PMID:
18697336
17.

Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.

Sesti G.

Diabetes Obes Metab. 2009 Dec;11 Suppl 3:4-10. doi: 10.1111/j.1463-1326.2009.01072.x. Review.

PMID:
19878256
18.

Incretins and amylin in pediatric diabetes: new tools for management of diabetes in youth.

Wood JR, Silverstein J.

Curr Opin Pediatr. 2013 Aug;25(4):502-8. doi: 10.1097/MOP.0b013e328362fdfb. Review.

PMID:
23782574
19.

Managing postprandial glucose levels in patients with diabetes.

Tenzer-Iglesias P, Brunton S.

J Fam Pract. 2008 Jan;57(1 Suppl Managing):S17-24. Review. No abstract available.

PMID:
18662529
20.

DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?

Halimi S.

Diabetes Metab. 2008 Feb;34 Suppl 2:S91-5. doi: 10.1016/S1262-3636(08)73400-1.

PMID:
18640591

Supplemental Content

Support Center